Managing director of Bharat Biotech Dr Krishna Ella has said that the biotechnological company’s nasal vaccine for Covid-19 is currently under its phase 1 trial
Bengaluru: India could very well launch the world’s first nasal vaccine for Covid-19.
Managing director of Bharat Biotech Dr Krishna Ella has said that the biotechnological company’s nasal vaccine for Covid-19 is currently under its phase 1 trial, as reported by Republic TV.
The website adds that May 8 is the deadline fixed for the same.
#DrEllaSpeaksToArnab | If you have taken injectable vaccine, one dose of nasal vaccine will stop transmission. We have seen no fever or infection in nasal vaccine trials. WHO is getting convinced now : Dr Krishna Ella, Bharat Biotech MD— Republic (@republic) April 24, 2021
Watch live here: https://t.co/jghcajZuXf pic.twitter.com/O0Kv1P1Xgt
“Injectible vaccines only protect up to lower lung, but the upper lungs and nose are not protected. People vaccinated may get an infection. But the vaccine will prevent you from hospitalisation. You might get a fever for two-three days. But mortality will be reduced,” he was quoted as saying to Republic TV.
It is to be added that taking a single dose of the nasal vaccine will help break the chain of transmission and further the process of flattening the curve of Covid-19 infections.
“If you take one dose of nasal vaccine you could block the infection and thereby block the transmission chain and then you can flatten the curve. It is just about four drops like polio, two in one nostril and two in the other. Now global authorities like the WHO are getting convinced about nasal as a second-generation vaccine,” Republic TV added him further as saying.
Last Updated Apr 25, 2021, 2:08 PM IST